The launch of Heme Libra, a 28-day hemophilia treatment, revealed a key challenge: patients accustomed to daily infusions were scared to trust the new, infrequent therapy. This shows that marketing truly disruptive products requires building trust and overcoming ingrained user habits, going beyond just demonstrating clinical superiority.

To overcome resistance, AI in healthcare must be positioned as a tool that enhances, not replaces, the physician. The system provides a data-driven playbook of treatment options, but the final, nuanced decision rightfully remains with the doctor, fostering trust and adoption.

Even with strong data supporting targeted agents, respecting a patient's decision to refuse them due to fears about side effects is a reasonable approach. Proceeding with standard chemotherapy and immunotherapy in such cases is a valid clinical choice that prioritizes shared decision-making and patient autonomy.

The modern oncologist-patient relationship involves highly informed patients who actively research their condition. They bring specific clinical trial papers to appointments, questioning physicians about median PFS data and control arms, requiring a more collaborative and data-driven discussion about their care.

To gain physician trust, AI companies must move beyond proving their algorithm is accurate. The gold standard is large-scale clinical evidence demonstrating tangible improvements in patient outcomes, treatment rates, and decision-making speed.

The medical system can default to providing more intensive care, but this isn't always beneficial; sometimes 'less is more.' Patients should feel empowered to ask critical questions like, "How likely am I to benefit from this?" and "Could I be better off with less aggressive therapy?" to ensure the chosen path is truly right for them.

Actuate Therapeutics demonstrates a patient-first ethos by having a dedicated group that not only helps patients access their own trials but also guides them to other companies' trials if those are a better fit. This builds community trust and prioritizes patient outcomes over proprietary interests.

A key feature of the new ASH-AYA-ALL guidelines is their transparency about evidence limitations. When insufficient data exists for a specific clinical question, the guidelines deliberately avoid making a firm recommendation. Instead, they explain why a recommendation cannot be provided, highlighting areas for future research and guiding clinicians through uncertainty.

While providing information is key, patient-centric care means recognizing that not every patient wants all the details of their disease. The ultimate empowerment is giving patients the agency to choose their level of involvement, including the option to trust their medical team without deep engagement.